BRAF and neoplasm: In particular, the BRAF inhibitors vemurafenib and GSK2118643 show evidence of clinical activity in a large proportion of patients whose tumours harbour BRAFV600E/K mutations (Flaherty et al, 2010; Kefford et al, 2010; Chapman et al, 2011).